March 05, 2026|The AG Line
Introduction
On February 2, 2026, a multistate coalition of 48 states and territories announced settlements totaling $17.85 million with Lannett Company, Inc. “Lannett”) and Bausch Health US, LLC and Bausch Health Americas, Inc (“Bausch”). Lannett and Bausch are pharmaceutical companies that manufacture and sell generic prescription drugs. The allegations are that each participated in long running conspiracies to artificially inflate and manipulate prices, limit competition, and unreasonably restrain trade for numerous generic prescription drugs.
These settlements are part of a larger multistate antitrust investigation and litigation track focused on alleged collusion among generic drug manufacturers, underway since 2016, and now headed toward a first trial in late 2026 in Hartford, Connecticut.
How the States See It
The states are framing the Lannett and Bausch settlements as part of a long running, multistate antitrust campaign focused on alleged collusion in the generic drug market. The core claim is not that prices rose in a hard market. It is that competitors allegedly coordinated pricing, bids, and market behavior in ways that restrained competition across numerous drugs for years, leaving consumers and payors paying more for essential medications than they should have.
The states are also positioning this as an active docket with a repeatable infrastructure behind it. They point to three related antitrust complaints filed over time, a record built through coordinated investigations, and a string of cooperation agreements and settlements that the states are using to press claims against remaining corporate defendants and individual executives. The states’ public messaging makes clear this is still moving toward a first trial in late 2026 in Hartford, Connecticut.
From Practice to Pleading
The states’ complaints and press materials read like a map of competitor contact, who talked to whom, when, and what happened next. They focus less on abstract antitrust concepts and more on a few repeat mechanics that the states say show up across the alleged conspiracies.
- Competitor contact that becomes the backbone of the story
The states describe executives from competing manufacturers regularly communicating and meeting, at industry events, social gatherings, and private meetings. In the states’ telling, those touchpoints are not background. They are the setting where coordination takes shape and where the lines between competition and collusion get tested. - Communications that let the states reconstruct timing and intent
The states emphasize the depth of the record, millions of documents, detailed call records, and contemporaneous notes kept by cooperating witnesses that memorialize discussions among competitors and internal company meetings. In a multistate case, the story is often built by lining up communications patterns with real world commercial moments, pricing moves, bid timing, and shifts in market behavior. - Language that normalizes coordination and signals expectations
The states highlight coded phrases such as “fair share,” “playing nice in the sandbox,” and “responsible competitor” as examples of how participants allegedly disguised unlawful agreements and reinforced a culture of collusion. The point is not the slogans themselves. It is that the states treat language as evidence of shared understandings and enforcement of the rules of the road.
The through line is scale and repeatability. The states are not just alleging harm in the abstract. They are alleging a pattern of competitor contact and communications, reinforced over time, that they say can be reconstructed across a broad market.
Monday Morning Checklist
- Map competitor contact points.
Pick one real setting where competitor contact happens and make the rules concrete.
- Who is authorized to engage
- What topics are off limits
- What gets documented, and where it lives
- Pressure test pricing and bidding escalation.
Identify who approves pricing and bids, and what happens when competitor information shows up. Keep it practical and fast. - Write the one-page competition narrative.
Not a policy. A one-page description leadership can stick to on short notice.
- What drives pricing and bids
- What guardrails exist
- Where the supporting records are
Closing Thought
The Lannett and Bausch settlements are news because of the dollars and the timing. They are also a reminder of how multistate coalitions pursue antitrust matters at scale, including cooperation expectations and compliance terms that extend well beyond the settlement announcement.
If your industry has regular competitor touchpoints, bid dynamics, or benchmarking practices, it is worth pressure testing your controls and your story now. Our team helps companies do that in a way that is practical, specific, and defensible. Reach out to us by email for more information on how we can help.
This communication is not intended to create or constitute, nor does it create or constitute, an attorney-client or any other legal relationship. No statement in this communication constitutes legal advice nor should any communication herein be construed, relied upon, or interpreted as legal advice. This communication is for general information purposes only regarding recent legal developments of interest, and is not a substitute for legal counsel on any subject matter. No reader should act or refrain from acting on the basis of any information included herein without seeking appropriate legal advice on the particular facts and circumstances affecting that reader. For more information, visit www.buchalter.com.
